Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.

Excess prepregnancy maternal BMI tied to interruption of breastfeeding

12 Apr 2018

Excess maternal body mass index (BMI) during prepregnancy seems to be associated with cessation of exclusive breastfeeding (EBF), according to a recent study.

Researchers performed a systematic review across six databases – PubMed, Scopus, Science Direct, LILACS, CINAHL and Web of Science – and identified 17 eligible studies, which were then subjected to a meta-analysis. Univariate meta-regression was used to determine the pooled effect of maternal prepregnancy BMI on EBF.

The pooled analysis showed that mothers with excess BMI prior to pregnancy were significantly more likely to interrupt EBF than mothers with normal BMI (effect size, 1.60; 95 percent CI, 1.47–1.74; p=0.000).

In general, the individual studies showed a similar trend, with the strongest effect size being 5.61 (4.31–7.66), reflecting the effect of overweight on EBF.

Moreover, the effect remained strong and significant even after excluding three studies with the strictest definition of EBF: mothers with excess BMI were approximately 60-percent more likely to interrupt EBF than their normal-weight counterparts.

“More studies are needed, mainly to assess the cessation of EBF and [for] greater comparability with respect to the cutoff point of EBF duration. There is also a need to use comparable cutoff points for the classification of prepregnancy maternal BMI,” said researchers.

“Further efforts to understand the possible determinants, confounders and even mediators of this association should also be emphasized,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
6 days ago
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.
Pearl Toh, 07 Dec 2018
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
2 days ago
Rates of major bleeding events are similar across cancer patients taking direct oral anticoagulants (DOAC), low-molecular-weight heparin (LMWH) or vitamin K antagonist (VKA), with gastrointestinal bleeding being the most frequent event, a recent study has shown. In addition, DOAC and LMWH recorded higher rates of venous thromboembolism than earlier studies.